news

SOUTH SAN FRANCISCO, Calif. and CUPERTINO, Calif., Jan. 14 /PRNewswire- FirstCall/ — Pain Therapeutics, Inc. (Nasdaq: PTIE) and DURECT Corporation (Nasdaq: DRRX) today announced they have signed an exclusive licensing agreement to formulate certain long-acting opioid drugs. Opioid drugs, sometimes called ‘narcotic painkillers,’ are widely used to treat moderate to severe pain. In the U.S., […]

CUPERTINO, Calif., Jan. 2 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 21st Annual Healthcare Conference. The conference is taking place January 6-9th at The Westin St. Francis Hotel in San Francisco. Dr. James E. Brown, President and Chief Executive Officer will be presenting at the conference

CUPERTINO, Calif., Dec. 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company has appointed David R. Hoffmann to its Board of Directors to replace Matthew V. McPherron who is stepping down as a member of the Board of Directors. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “Matt McPherron has served DURECT very well during the past

CUPERTINO, Calif., Nov. 22 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today announced that it is reducing operating expenses in accordance with the Company’s overall corporate objectives for the fiscal year 2003. DURECT’s long-term strategy and business plan remain on track. The Company is reducing personnel levels to focus specifically on the CHRONOGESIC(TM) product and development

ZUG, Switzerland and CUPERTINO, Calif., Nov. 19 /PRNewswire-FirstCall/ — BioPartners, a global biopharmaceuticals company and one of the leaders in the emerging field of competitively priced multi-source biopharmaceuticals, has signed an exclusive agreement with DURECT Corporation (Nasdaq: DRRX), a U.S. based pioneering pharmaceutical systems company, for the development of a sustained release formulation of recombinant

CUPERTINO, Calif., Nov. 14 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) and Thorn BioScience LLC announced today that the two companies have expanded their agreement for the development and commercialization of veterinary products for reproductive indications using DURECT’s SABER(TM) Delivery System. The SABER technology has the potential to successfully deliver therapeutic levels of a wide spectrum

CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has amended its development and commercialization agreement with ALZA Corporation under which DURECT holds exclusive rights to develop, commercialize and manufacture products using ALZA’s patented DUROS(R) technology in selected fields of use. Under the amended agreement, DURECT’s maintenance of exclusivity in

CUPERTINO, Calif., Nov. 12 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2002. (Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) DURECT’s net loss for the three months ended September 30, 2002 was $9.1 million or 19 cents per share, compared to $8.9 million or 19 cents per share for the

CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will postpone its third quarter financial results press release and conference call to Tuesday, November 12th, 2002. The earnings release is postponed due to the announcement today by DURECT Corporation and Endo Pharmaceuticals relating to the agreement to collaborate on the

CHADDS FORD, Pa. and CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ — Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP) and DURECT Corporation (Nasdaq: DRRX), announced today that they have signed an agreement to collaborate on the development and commercialization of DURECT’s CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the U.S. and Canada. The companies believe CHRONOGESIC has significant potential